Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse

Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares 
of Common Stock, Listing on NASDAQ, Reverse Stock
Split 
SAN DIEGO, CA -- (Marketwired) -- 12/13/13 --  Adamis Pharmaceuticals
Corporation (NASDAQ: ADMP) today announced the pricing of an
underwritten public offering of 3,720,000 shares of common stock at
an offering price of $5.95 per share. The gross proceeds to Adamis
from this offering are expected to be approximately $22,134,000,
before deducting underwriting discounts and commissions and other
estimated offering expenses. All of the shares in the offering are
being sold by Adamis. The offering is expected to close on December
18, 2013, subject to customary closing conditions. In connection with
the offering, Adamis has completed a 1-for-17 reverse stock split of
its common stock which is effective as of December 13, 2013. The
common stock began trading, on a split-adjusted basis, on The NASDAQ
Capital Market under the symbol "ADMP" on December 13, 2013. In
connection with its listing on The NASDAQ Capital Market, the
company's common stock will cease trading on the OTC QB.  
CRT Capital Group, LLC is acting as sole book-running manager for the
offering, and Newport Coast Securities, Inc. is acting as co-manager
of the offering. Adamis has granted the representative of the
underwriters a 30-day option to purchase up to a maximum of 558,000
additional shares of common stock from Adamis to cover
over-allotments, if any.  
Adamis intends to use approximately $7 million of the net proceeds
from the offering to make the final payment to acquire the assets
relating to the Taper dry powder inhaler technology pursuant to an
agreement that the company entered into earlier this year. An
additional approximately $7.2 million of the net proceeds are also
expected to be used to pay in full all amounts owed under unconverted
convertible promissory notes that were issued in a private placement
financing transaction in June 2013. Remaining net proceeds are
expected to be used to fund the filing and launch of the Epinephrine
PFS product candidate, fund clinical trials, and for working capital
and general corporate purposes, including payment of outstanding
obligations and indebtedness.  
A registration statement on Form S-1 relating to the shares of common
stock offered by the company was filed with the Securities and
Exchange Commission and is effective. A preliminary prospectus
relating to the offering has been filed with the SEC and is available
on the SEC's web site at http://www.sec.gov. Copies of the final
prospectus relating to the offering, when available, may be obtained
from CRT Capital Group LLC, 262 Harbor Drive, Stamford, CT 06902, or
from the above-mentioned SEC website. 
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, these securities, nor will there be
any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale is not permitted. 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is a biopharmaceutical company
engaged in the development and commercialization of specialty
pharmaceutical and biotechnology products in the therapeutic areas of
respiratory disease, allergy, oncology and immunology. The company's
current specialty pharmaceutical product candidates include the
Epinephrine Injection PFS syringe product for use in the emergency
treatment of anaphylaxis, APC-1000 and APC-5000 for the treatment of
asthma and chronic obstructive pulmonary disease, and APC-3000, an
HFA inhaled nasal steroid product for the treatment of allergic
rhinitis. The company's vaccine product candidates and cancer drug
product candidates under research and development include TeloB-VAX,
a cell-based therapeutic cancer vaccine and three drugs, APC-100,
APC-200, and APC-300, for the treatment of prostate cancer. 
Adamis Contacts 
Mark Flather
Director, Investor Relations &
Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951
mflather@adamispharma.com